# Pacific Biosciences of California, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pacific Biosciences of California, Inc). ## Overview Pacific Biosciences of California is a U.S.-based life science technology company that designs, develops, and manufactures DNA sequencing systems and consumables. Its core platform is HiFi long-read sequencing, used to generate highly accurate views of genomes, transcriptomes, and epigenomes for research and clinical applications. ## Products & services • HiFi long-read sequencing systems • Sequencing consumables and reagents • Service and maintenance agreements • Sequencing workflow and support services - **Instruments** (34%) — Sequencing platforms sold to laboratories for genome analysis and related applications. - **Consumables** (51%) — Reagents and other recurring-use materials consumed on installed sequencing systems. - **Service and other** (15%) — Maintenance agreements, support, and other service-related revenue. - HiFi long-read sequencing systems - Sequencing consumables and reagents - Service and maintenance agreements - Sequencing workflow and support services ## Customers PacBio sells to research and clinical laboratories that need long-read sequencing for complex genomic analysis. Its customer base includes academic and government institutions, genome centers, hospitals, CROs, pharmaceutical companies, agricultural companies, and commercial testing labs. Many customers buy instruments first and then generate recurring consumables demand as they run samples over time. - **Academic and government research** (primary) — Buy sequencing systems and consumables for basic and translational genomics research. - **Clinical and hospital labs** (primary) — Use HiFi sequencing for rare disease, inherited disease, oncology, and clinical research. - **Commercial testing and service labs** (secondary) — Purchase systems to sequence samples for third parties and generate service revenue. - **Pharmaceutical and CRO customers** (secondary) — Use the platform for drug discovery, biomarker work, and complex genomic workflows. - **Agricultural and applied science customers** (secondary) — Use long-read sequencing for plant and animal science applications. - Academic and governmental research institutions - Genome centers and public health laboratories - Hospitals and clinical research institutes - CROs and commercial testing/service laboratories - Pharmaceutical and agricultural companies ## Geography PacBio is headquartered in the United States and sells through a global direct sales force plus distribution partners. The company serves customers across North America, Europe, the Middle East, Africa, Asia, Australia, and the Americas, which makes international adoption and export access important to growth. Its operating footprint and partner network matter because sequencing systems are sold into specialized research and clinical markets that are concentrated in major scientific hubs. - Headquartered in the United States - Global sales force supports direct commercial coverage - Distribution partners cover parts of Asia, Europe, MEA, and the Americas - International market access matters for instrument placements and consumables pull-through ## Strategy PacBio’s strategy centers on expanding adoption of HiFi long-read sequencing across research and clinical use cases. It aims to improve throughput, simplify workflows, lower sequencing cost, and broaden the installed base so consumables revenue grows with instrument placements. The company also relies on partnerships and third-party tools to strengthen sample preparation, informatics, and market reach. - **Drive platform adoption** (medium-term) — Instrument placements create recurring consumables demand and deepen customer relationships. - **Broaden applications** (medium-term) — More use cases increase the addressable market and reduce dependence on a narrow set of buyers. - **Strengthen commercial execution** (short-term) — A specialized sales and support model is needed to convert scientific interest into placements. - Expand HiFi sequencing adoption in research and clinical markets - Grow consumables revenue through installed-base expansion - Improve throughput and workflow simplicity - Lower cost per genome to widen addressable demand - Use partners for distribution, leasing, and customer support ## Risks PacBio faces intense competition from larger and better-resourced sequencing companies, which can pressure pricing and slow adoption. Its business also depends on customer acceptance of new platforms, third-party sample prep and informatics tools, and continued access to international markets; large customer orders can create quarter-to-quarter volatility. Because the company has historically operated at a loss and may need external capital, execution and funding risk remain important. - **Competitive pressure in nucleic acid sequencing** [high] — Rivals may have greater resources, broader installed bases, and faster product development. - **Customer concentration and order timing** [high] — A limited number of large purchase orders can cause material revenue volatility. - **Product adoption and ecosystem dependence** [medium] — Demand depends on third-party sample prep and informatics tools that may be delayed or unavailable. - **Export and regulatory restrictions** [medium] — Future U.S. export controls could limit sales to certain countries or applications. - **Capital needs and operating losses** [high] — The company has historically generated negative operating cash flow and may need external funding. - Intense competition from established and emerging sequencing rivals - Customer adoption depends on platform performance and workflow compatibility - Large orders from a limited number of customers can swing quarterly revenue - Export controls could restrict sales into certain countries - Ongoing losses may require additional capital to fund growth ## Accounting PacBio’s revenue recognition is driven by a mix of instrument sales, consumables, and service agreements, so the timing of placements versus recurring usage affects reported revenue. Investors should also watch quarter-to-quarter volatility from large customer orders, inventory reserves, and product mix, since these can move gross margin and comparability. Estimates around intangible assets, warranty costs, and any future impairment testing can also affect reported results. - **Revenue recognition by product line** — Affects revenue timing and mix - **Quarterly volatility from large orders** — Affects comparability and forecasting - **Inventory reserves and warranty estimates** — Affects gross margin and operating results - **Intangible asset and impairment testing** — Can create non-cash charges - Revenue timing differs across instruments, consumables, and service contracts - Large purchase orders can create quarter-to-quarter revenue swings - Product mix affects gross margin and cost of revenue - Inventory reserves and warranty estimates can change reported profit - Intangible asset and impairment judgments may affect balance-sheet values --- *Last updated: 2026-09-24T11:13:38.308955+00:00*